Celltrion announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, tocilizumab-anoh) in both an intravenous (IV) ...
Alumis Inc. (Nasdaq: ALMS) and ACELYRIN, Inc. (Nasdaq: SLRN) today announced a definitive merger agreement, creating a powerhouse in immunology-focused b...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced it has amended its agreement with Takeda to develop and commercialize osavampator (NB...
Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement from X4 that their Marketing Authorization Applicatio...
Tevogen Bio Holdings Inc. (“Tevogen Bio” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech d...
AbbVie (NYSE: ABBV) and Neomorph, Inc. announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple tar...
Tanvex BioPharma, Inc. (“Tanvex”), a contract development and manufacturing organization (CDMO) for biologics and a biosimilars product...
Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to redefining the retina ex...
Kindeva Drug Delivery’s global health security division, Meridian Medical Technologies, LLC, secured a contract valued at up to $129 million t...
Labviva, the leading AI procurement platform for life sciences, announced the close of its $25 million Series B, bringing its total funding to ...
Eli Lilly and Company (NYSE: LLY) and Scorpion Therapeutics, Inc. ("Scorpion"), a private biotechnology company developing small ...
GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based, c...
The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-own...
Company embarks on a vision to make cardiovascular disease curable, preventable, and no longer the leading cause of death worldwide Led by found...
© 2025 Biopharma Boardroom. All Rights Reserved.
